Online inquiry

IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ2773MR)

This product GTTS-WQ2773MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RL1 gene. The antibody can be applied in Allergic asthma research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001282408.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	9173
UniProt ID	Q01638

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2773MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ2729MR	IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	AMG-139
GTTS-WQ15252MR	IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	Tarvacin ch3G4
GTTS-WQ1631MR	IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ACE-910
GTTS-WQ15312MR	IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	TNFR55-Ig1
GTTS-WQ12665MR	IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	OMP-18R5
GTTS-WQ13190MR	IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	PF-04950615
GTTS-WQ11889MR	IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	MLN-0264
GTTS-WQ13825MR	IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	REGN-10987

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST